External defibrillator MDR guidance
This article was originally published in The Gray Sheet
Executive Summary
FDA meets with manufacturers and user groups on Sept. 23 to discuss a Sept. 9 guidance outlining medical device reporting requirements for external defibrillators. At the meeting, the agency also summarized concerns about product recalls and violations of good manufacturing practices and MDR provisions. The agency also asked for input on how automatic external defibrillator performance levels can be validated and how their clinical reliability can be determined. FDA held a similar meeting in July with user groups, but it was closed to manufacturers ("The Gray Sheet" Aug. 15, p. 30)
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.